Clinical trial registry record

Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 4, 2023.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT00406393
Last registry update
January 4, 2023
Status
Completed
Phase
Phase 3
Sponsor
Medical College of Wisconsin
Enrollment
304
Countries
United States, France
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
304
Population
ALL · 2 Years to 60 Years
Duration
2006-11-01 to 2015-10-01
Intervention
Tacrolimus; Methotrexate; Sirolimus
Comparator
Tacrolimus/Methotrexate
Outcomes measured
Rate of Grades II-IV Acute GVHD-free Survival — Day 114; Incidence of Acute GVHD — Measured at Day 100; Time to Neutrophil and Platelet Engraftment — Measured through Day 100; Mucositis Severity — Measured at Day 21; Rate of Veno-occlusive Disease (VOD) — Measured through Day 100; Thrombotic Microangiopathy (TMA) Infection — Measured through Day 100; Reactivation of Cytomegalovirus (CMV) Infection — Measured at Year 2; Treatment-related Mortality — Measured at Day 100 and Year 2; Malignant Disease Relapse — Measured at Year 2; Overall Survival — Measured at Year 2; Infections — Measured at Year 2; Time to Discharge After Transplant — Measured at Year 2
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON